在我国的中药行业里，康缘药业是一家少有的自带创新基因，肯在研发上下大功夫的企业。但在整个中药市场承压的大环境里，依然要想办法跨界破局。 撰文| 石若萧 润屿 继科源制药与宏济堂宣布资产重组后，中药领域又现并购。

The brokerage highlighted that there are several growth opportunities for the company going ahead including the growing CS ...

Pendulum Therapeutics latest innovation comes in the form of a GLP-1 probiotic, acting as an appetite suppressor and healthy ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Coverage for these medications varies widely across plans; while many employers cover GLP-1 for diabetes treatment, fewer ...

Once-weekly semaglutide shows significant reduction in knee osteoarthritis pain and body weight in adults with obesity, a ...

A RECENT study highlights a concerning link between the use of GLP-1 receptor agonists (GLP-1RA) and inadequate bowel ...

There's a new player in the running game, and it's not the latest carbon-plated shoe or fancy GPS watch. GLP-1 medications ...

Analyzing H&H's Q3 results and investment strategy in the healthcare industry, highlighting undervaluation and raising the ...

On October 3, Amy Kane, 35, who once weighed 300 pounds at her heaviest, garnered 1.7 million views (@amyinhalf) after ...

People are more likely to develop type 2 diabetes if they are: Experts with UW Health say it is important to remember the ...

We rate McKesson as a 'Strong Buy' with focus on GLP-1 meds, oncology network, and strong Q2 results driving future growth.